Drug Discovery Article Competition
Join the prestigious Drug Discovery Article Competition and showcase your work.
List view / Grid view
Articles
New drug boosts foetal haemoglobin to fight sickle cell disease
Researchers are exploring the potential use of HDAC inhibitors, a group of drugs known for their capability to impede tumour cell division, to reduce the pain and damage associated with sickle cell disease. The drugs have shown initial evidence of reactivating the gene responsible for producing foetal haemoglobin, which cannot…
New insight into BRCA2 gene mutations and cancer risk
A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovarian cancer.
Challenges and promises of personalised precision medicine
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
CRISPR and single-cell sequencing highlight genetic variants for traits and diseases
This article highlights a new approach to address human genetics, using STING-seq which provides roadmap to identify variants and genes, enabling deeper understanding of the noncoding genome and targets for therapies
Light-activated graphene tattoo shows promise in treating heart rhythm disorders
This article outlines the development of the first cardiac implant made from graphene, which is thinner than a single strand of hair yet still functions like a classical pacemaker. It melds softly to the heart to simultaneously sense and treat irregular heartbeats, making it ideal for conforming to soft, dynamic…
Revolutionary nanoparticles enable gene-editing in lungs
This article outlines the development of a new type of nanoparticle that can perform gene-editing in the lungs. Scientists from MIT and the University of Massachusetts Medical School have collaborated to create this Ribonucleic acid (RNA) delivery particles, which have the potential to revolutionise the treatment of lung diseases such…
ebook: Never Miss A Hit – Unleash Your Drug Discovery With A Label-Free Playlist
Get ready to dive into the cutting-edge world of hit-to-lead drug discovery. Look no further than our latest FREE ebook, which explores label-free HTL technologies. Featuring the latest research from leading academics and pharmaceutical companies, including GlaxoSmithKline, Rosalind Franklin Institute and Francis Crick Institute.
2023 drug discovery forecast: emerging trends and disruptors revolutionising the industry
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.
The role of ABCs in lupus: insights for developing precision therapies
Researchers from the University of Pittsburgh have found that age-associated B cells (ABCs) are key drivers of lupus, a chronic autoimmune disorder that attacks the patient's own organs.
Yersinia bacteria: can it be eliminated in the intestine?
This article outlines new research from the University of Pennsylvania, concerning Yersinia pseudotuberculosis, a relative of the bacterial pathogen that causes plague by triggering the body’s immune system to form lesions in the intestines.
SARS-CoV-2 spike protein dihedral angle oscillations reveal favoured rotation frequencies
As new variants of the SARS-CoV-2 virus emerge, leading scientists Dr Oscar Bastidas and Dr Zoran Sevarac explore how their latest research identified a structured frequency domain profile in data with no discernible pattern. Their article also emphasises that it remains imperative to continue learning about this pathogen’s molecular machinery…
Assay performance and the Z’-factor in HTS
Matthew Lloyd from the University of Bath reveals the importance of the Z-factor and Z’-factor in high-throughput screening, and how they can be used to determine assay performance, perform quality control on the screen, and identify active compounds.
An approach to mRNA vaccine development in the wake of COVID-19
Brad Sorenson, CEO of Providence Therapeutics, shares the future developments and exciting potential of mRNA therapies, including improved efficacy and wider access to vaccines, and future promise for cancer treatment.
De-risking drugs in multiplex assays before progressing to clinical trials
Sheraz Gul, Head of Assay Development and Drug Repurposing at the Fraunhofer Institute, discusses the importance of performing comprehensive multiplex spatial and temporal profiling of drugs in pre-clinical research to decrease the risk of potentially undesirable events in later clinical studies.